In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
In a study of hemodialysis patients, pre-operative potassium higher than 3.9 mmol/L correlated with greater risk for hyperkalemia after parathyroidectomy.
In the DIALIZE trial, 41.2% of hemodialysis patients taking sodium zirconium cyclosilicate maintained normal potassium levels during the long interdialytic interval compared with just 1% receiving placebo.
In a study of chronic kidney disease patients not on dialysis, hyperkalemia developed in more women than men.
Hyperkalemia in patients undergoing cardiac surgery is associated with increases risks for postoperative death, cerebrovascular accidents, and need for dialysis.
In a small study on nondialysis CKD patients, daily potassium intake was not associated with hyperkalemia (serum potassium level above 5 mEqL) in patients with chronic kidney disease.
In a large, population-based study, patients prescribed sodium polystyrene sulfonate had a nearly 2-fold higher risk of adverse GI events within 30 days of initial prescription.
Hyperkalemia, defined as a serum potassium level above 5.3 mmol/L, develops in many patients with chronic kidney disease (CKD). The abnormality can precipitate serious adverse outcomes, including dysrhythmias and sudden cardiac death, so patients with elevated blood potassium levels may be referred to emergency departments or urgent care facilities for immediate therapy. As a result,…
In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.
It is challenging for CKD patients to stay on spironolactone therapy because it can increase the risk of hyperkalemia, according to researchers.